Barriers to overcome in lupus drug development
10:38 EDT 22 Jul 2012 | thePharmaLetter
It has taken the lupus research community over 50 years to produce a new therapy. Although it is now a year old, Benlysta (belimumab), now marketed by GlaxoSmithKline and Human Genome Sciences, is the first human monoclonal antibody for the treatment..
Original Article: Barriers to overcome in lupus drug development
More From BioPortfolio on "Barriers to overcome in lupus drug development"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
